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Cervical Cancer Screening Measures Need to Evolve to Continue 
to Tell the Story
Mona Saraiya, M.D., M.P.H., Meg Watson, M.P.H., and Vicki B. Benard, Ph.D.
Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and 
Health Promotion, Division of Cancer Prevention and Control, Epidemiology and Applied 
Research Branch, Atlanta, Georgia
According to Chen et al.,1 6% of U.S. adult women reported never having been screened for 
cervical cancer. These women were young (< 21 years) or old (≥ 70 years), less educated, 
uninsured, Hispanic, widowed, and never married. Besides the focus on the never screened 
women, this study offers many insights into the successes, failures, and gaps of cervical 
cancer screening over the past two decades. Additionally, it gives public health professionals 
who develop and use survey measures issues to consider in finding the right balance between 
keeping the survey consistent to allow for interpretation of trends and flexibility to allow 
measurement of emerging technologies and new practices.
One important success not fully appreciated in the article by Chen et al. is that for the first 
time, in 2012, cervical cancer screening guidelines are consistent among the three national 
organizations2–4 (www.cdc.gov/cancer/cervical/pdf/guidelines.pdf for table), including 
consensus that women <age 21 years no longer need to be screened. Chen’s Behavioral Risk 
Factor Surveillance System (BRFSS) analysis foreshadows this sentinel event by 
documenting that the percentage of young women <21 years who report never being 
screened increased from 35% in 1993 to 54.3% in 2010. This could be a result of concern 
over the increased adverse pregnancy outcomes associated with screening before the 
recommended age or the aggressive treatment of preclinical lesions that have a long latency 
period and a strong likelihood of regression.5,6 We expect that the decline that we are seeing 
now will continue to be observed in future surveys. A lower proportion of women reported 
screening in the past year (from 64.5% in 1993 to 54.1% in 2010); this finding may signal 
the wave of the future because of the call by all three organizations for an end to annual 
cervical cancer screening. Additionally, the Chen et al. article highlights that screening 
continues among women with a hysterectomy when recommendations for this have been 
consistent for 10 years.7–9 Why do half of women who have had a hysterectomy report 
having had a Pap test within the past 3 years? Surely, we cannot expect that all these women 
have had a supracervical hysterectomy or a history of treatment for cervical intraepithelial 
neoplasia (CIN2) and still require a Pap test. The aim of measuring screening failure is to 
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avoid harm for women at lowest risk and target resources for women at highest risk of 
getting cervical cancer.
Over half of cervical cancers in the United States occur among women who have never been 
screened.10 There has remained a constant proportion of women who have never received a 
Pap test since the 1990s—approximately 6%. Who are the elderly women > 70 years of age 
who have never had a Pap test? Chen et al. could identify only characteristics currently 
collected, which do not include language spoken, country of birth, in BRFSS, or specific 
Hispanic subgroups, all characteristics of women who have been reported to be less likely to 
get screened.11 Additional measures not addressed include newer technologies, such as 
human papillomavirus (HPV) testing and HPV vaccination status. HPV and Pap testing 
together (cotesting) has been an approved option in screening since 2003 according to some 
organizations. By 2012, all organizations now either strongly recommend or include 
cotesting as an option for women ≥ 30 years of age. If both tests are negative, women can 
now extend the screening interval to 5 years, a response option that needs to be incorporated 
with in surveys that measure current screening behaviors and practices.
Questions on HPV vaccination status would address the interpretation of screening 
behaviors. There is concern that vaccinated girls and women may have a false sense of 
security and, thus, not follow recommended screening guidelines. Although current 
guidelines remain the same for vaccinated and nonvaccinated women,2 it is anticipated that 
in the future screening fully vaccinated girls can occur later and less often.12 In the United 
States, self-reported state and national surveys are heavily relied upon to measure screening 
prevalence and gaps for cervical cancer screening, largely because a nationwide population-
based screening program does not exist. Long-standing national and state-based surveillance 
systems face a tough challenge in being responsive to changes in communications 
technology, population diversity, and newer technologies while still allowing measurement 
of trends.12 The same issues are salient and relevant to the international setting. The World 
Health Organization Global Monitoring Framework currently proposes an indicator to 
measure that women between the ages of 30 to 49 years have been screened for cervical 
cancer at least once.13 With international efforts focused on cervical cancer in low- and 
middle-income countries, we may need to leverage existing surveillance systems that ask 
standardized core sets of questions for cervical cancer screening, whether the screening 
method is using the HPV test, Pap test, or visual inspection with acetic acid (VIA). Clearly, 
cervical cancer measures can tell a story, but they will need to keep up with the times.
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